A 37-year-old woman experienced suspected biphasic anaphylaxis after her first known subcutaneous dose of tirzepatide, according to a case report published by Cureus. The patient required emergency treatment for respiratory and cardiovascular distress, followed by a second reaction an hour later, highlighting the potential for severe hypersensitivity reactions to the dual GIP and GLP-1 receptor agonist.
Tirzepatide, a synthetic 39-amino-acid peptide used for chronic weight management and type 2 diabetes mellitus, is generally well tolerated. However, a recent case detailed by Cureus documents a life-threatening systemic response that occurred immediately following a first dose.
Immediate and Recurrent Symptoms in the Tirzepatide Case
The patient presented with a rapid onset of multi-organ system involvement. Initial symptoms included hypotension, hypoxemia, bronchospasm, generalized urticaria, nasal congestion, and facial and periorbital angioedema. Medical staff treated the episode using two doses of intramuscular epinephrine, nebulized bronchodilators, and intravenous fluids, which led to a complete clinical resolution.
The recovery was short-lived. Approximately one hour after the initial resolution, the woman developed a second wave of symptoms without any further exposure to the drug. This recurrent episode involved chest tightness, facial angioedema, and generalized urticaria. While this second phase did not result in documented hemodynamic or respiratory compromise, it was categorized as a possible biphasic reaction.
To resolve the recurrent symptoms, clinicians administered chlorphenamine and intravenous hydrocortisone. Despite the severity of the reactions, the underlying immunological mechanism remains unconfirmed because baseline and acute serum tryptase levels were unavailable and no validated allergy testing for tirzepatide was performed.
Tirzepatide’s Mechanism and Reported Hypersensitivity
Tirzepatide functions as a dual agonist of the glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors. It is modified with a C20 fatty diacid moiety to extend its half-life. By activating these receptors, the drug reduces appetite centrally, delays gastric emptying, and suppresses glucagon secretion while enhancing glucose-dependent insulin secretion.
While most hypersensitivity reactions reported in post-marketing surveillance and clinical trials have been non-serious, there are documented instances of angioedema and anaphylaxis. According to the report in Cureus, a retrospective observational analysis has identified 43 published cases of adverse drug reactions associated with tirzepatide, spanning endocrine, hepatic, gastrointestinal, and dermatologic systems.
The exact frequency of these anaphylactic reactions is still uncertain. Most drug-induced anaphylaxis is mediated by IgE-dependent mast cell and basophil degranulation, which releases vasoactive mediators such as histamine, chymase, tryptase, and carboxypeptidase A3, as well as prostaglandins and leukotrienes.
Comparing Drug-Induced and Nutrient-Induced Reactions
Systemic hypersensitivity can occur across various medical interventions, though the triggers and management vary. While tirzepatide represents a modern pharmacological trigger, older literature highlights reactions to essential nutritional support. A case reported by pubmed.gov detailed a 52-year-old woman with pancreatic carcinoma who experienced hypersensitivity to total parenteral nutrition (TPN).
The TPN reaction manifested as hypoxia and dyspnea within 30 minutes of administration. Unlike the tirzepatide case, where the trigger was a specific synthetic peptide, the TPN reaction recurred even with lipid-free versions of the nutrition. Researchers speculated that a multivitamin preparation (MVI) might have been the cause, though this was not confirmed via epicutaneous allergy testing or MVI-free administration.
| Feature | Tirzepatide Case (Cureus) | TPN Case (pubmed.gov) |
|---|---|---|
| Patient | 37-year-old woman | 52-year-old woman |
| Primary Symptoms | Hypotension, angioedema, urticaria | Dyspnea, pruritus, hypoxia |
| Reaction Type | Suspected Biphasic Anaphylaxis | Hypersensitivity Reaction |
| Treatment | Epinephrine, steroids, antihistamines | Withholding TPN, antihistamines |
Clinical Vigilance and Pharmacovigilance
The global incidence of anaphylaxis is estimated between 50 and 112 episodes per 100,000 person-years. While mortality is low—estimated at less than one per million people annually—drug-induced reactions remain a significant portion of adult cases. Common triggers typically include NSAIDs, beta-lactam antibiotics, radiocontrast media, and neuromuscular blocking agents.
Clinicians must distinguish immediate hypersensitivity from delayed reactions, such as Stevens-Johnson syndrome or drug reaction with eosinophilia and systemic symptoms (DRESS), which typically appear days or weeks after exposure. The tirzepatide case underscores the need for prompt recognition of immediate systemic reactions and the importance of detailed reporting to improve the known safety profile of dual GIP/GLP-1 agonists.
Discover more from Archyworldys
Subscribe to get the latest posts sent to your email.